Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Authors
Van der Weijst, L.Aguado-Barrera, M. E.
Azria, D.
Berkovic, P.
Boisselier, P.
Briers, E.
Bultijnck, R.
Calvo-Crespo, P.
Chang-Claude, J.
Choudhury, Ananya
Defraene, G.
Demontois, S.
Dunning, A. M.
Elliott, R. M.
Ennis, D.
Faivre-Finn, Corinne
Franceschini, M.
Gutiérrez-Enríquez, S.
Herskind, C.
Higginson, D. S.
Kerns, S. L.
Johnson, K.
Mollà, M.
Lambrecht, M.
Ramos, M.
Rancati, T.
Rimner, A.
Rosenstein, B. S.
De Ruysscher, D.
Salem, Ahmed
Sangalli, C.
Seibold, P.
Sosa-Fajardo, P.
Sperk, E.
Stobart, H.
Summersgill, H.
Surmont, V.
Symonds, P.
Taboada-Lorenzo, B.
Talbot, C. J.
Valdagni, R.
Vega, A.
Veldeman, L.
Veldwijk, M. R.
Ward, T.
Webb, A.
West, C. M. L.
Lievens, Y.
Issue Date
2022
Metadata
Show full item recordAbstract
Objectives Radiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study. Materials and methods HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ≤ 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages. Results Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually. Conclusions While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals’ HRQoL, symptoms and toxicity in treatment decision-making.Citation
Van der Weijst L, Aguado-Barrera ME, Azria D, Berkovic P, Boisselier P, Briers E, et al. Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). Vol. 166, Lung Cancer. Elsevier BV; 2022. p. 228–41.Journal
Lung CancerDOI
10.1016/j.lungcan.2022.03.010PubMed ID
35334417Additional Links
https://dx.doi.org/10.1016/j.lungcan.2022.03.010Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2022.03.010
Scopus Count
Collections
Related articles
- The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
- Authors: van der Weijst L, Azria D, Berkovic P, Boisselier P, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Defraene G, Demontois S, Elliott RM, Ennis D, Faivre-Finn C, Franceschini M, Giandini T, Giraldo A, Gutiérrez-Enríquez S, Herskind C, Higginson DS, Kerns SL, Johnson K, Lambrecht M, Lang P, Ramos M, Rancati T, Rimner A, Rosenstein BS, De Ruysscher D, Salem A, Sangalli C, Seibold P, Sosa Fajardo P, Sperk E, Stobart H, Summersgill H, Surmont V, Symonds P, Taboada-Valladares B, Talbot CJ, Vega A, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Lievens Y, REQUITE consortium
- Issue date: 2022 Nov
- Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.
- Authors: Van Der Weijst L, Surmont V, Schrauwen W, Lievens Y
- Issue date: 2021
- Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
- Authors: Auchter RM, Scholtens D, Adak S, Wagner H, Cella DF, Mehta MP
- Issue date: 2001 Aug 1
- Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer.
- Authors: Ran J, Wang J, Bi N, Jiang W, Zhou Z, Hui Z, Liang J, Feng Q, Wang L
- Issue date: 2017 Dec 2
- Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
- Authors: Sztankay M, Giesinger JM, Zabernigg A, Krempler E, Pall G, Hilbe W, Burghuber O, Hochmair M, Rumpold G, Doering S, Holzner B
- Issue date: 2017 Aug 23